Clinical trials are research investigations in which people volunteer to test new treatments, interventions or tests as a means to prevent, detect, treat or manage various diseases or medical conditions.
Vigil is a fully personalized cancer immunotherapy utilizing genetically modified tumor cells. To date, we have conducted Phase 1 studies identifying the clinical dose and established the early safety profile for the platform.
The tumor types studied in Phase 1 included, but not limited to: Ovarian cancer, breast cancer, melanoma, Ewing’s sarcoma, non-small cell lung cancer, colon cancer, and hepatocellular cancer. We have also initiated Phase 2 studies in advanced ovarian cancer and Ewing’s sarcoma.
We are currently preparing to begin additional trials in advanced women’s cancers, as well as in combination with other immunotherapies, such as checkpoint inhibitors in patients with advanced women’s cancers.
